UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000014832
Receipt number R000017239
Scientific Title Examination of electrocardiogram QT intervals prolongation after taking Escitalopram
Date of disclosure of the study information 2014/08/15
Last modified on 2018/10/10 15:21:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Examination of electrocardiogram QT intervals prolongation after taking Escitalopram

Acronym

Examination of electrocardiogram QT intervals prolongation after taking Escitalopram

Scientific Title

Examination of electrocardiogram QT intervals prolongation after taking Escitalopram

Scientific Title:Acronym

Examination of electrocardiogram QT intervals prolongation after taking Escitalopram

Region

Japan


Condition

Condition

Major Depressive Disorder

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We examine the correlation between QT intervals measured by a 12 resting ECG and those measured by an ambulatory electrocardiogram, among the patients who are taking escitalopram, an antidepressant drug. After that, we examine whether the ambulatory electrocardiogram can discern the QT intervals which were prolonged by the drug. And we also examine whether the prolonged QT intervals correlate genetic polymorphism and the drug level each other.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Confirmation of the QT prolonged with taking Escitalopram

Key secondary outcomes

1)Correlation of the QT intervals measured by 12 instruction and mobile electrocardiograph
2)Prevalence of the QT value over 500msec
3)Observation of the QT value area according to the subjects background factor


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Escitalopram

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) The patient with major depressive disorder to meet a criteria of DSM-V
2) The patient who is over 20 years old at the agreement acquisition
3) The patient who understands enough the explanation about this examination and agrees on this study

Key exclusion criteria

1) The patient with a history of hypersensitivity for the ingredient of the study drug
2) The patient who is taking a monoamine oxidase (MAO) inhibitor or the patient who stops taking the drug within 14 days
3) The patient who is taking Pimozide
4) The patient who has QT interval over 500 msec
5) The patient who has long QT syndrome and arrhythmia to need treatment or the heart disorder (coronary artery disease, myocardial desease, valve disorder and heart failure)
6) The patient who is regarded as the inappropriate person by a doctor who is in charge of the examination

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kenichi Osada

Organization

St. Marianna University School Of Medicine

Division name

Neuropsychiatry

Zip code


Address

2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa

TEL

044-977-8111

Email

k2osada@marianna-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kenichi Osada

Organization

St. Marianna University School Of Medicine

Division name

Neuropsychiatry

Zip code


Address

2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa

TEL

044-977-8111

Homepage URL


Email

k2osada@marianna-u.ac.jp


Sponsor or person

Institute

St. Marianna University School Of Medicine

Institute

Department

Personal name



Funding Source

Organization

Mitsubishi Tanabe Pharma

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 08 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 08 Month 06 Day

Date of IRB


Anticipated trial start date

2014 Year 08 Month 20 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2017 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2014 Year 08 Month 11 Day

Last modified on

2018 Year 10 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017239


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name